Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Glargine U300 in Insulin-naïve T2DM Patients in Turkey
NCT02954692Phase 4Completed
- Sponsor
- Sanofi
- Start
- Nov 2016
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Mean change from baseline in HbA1c at 24 weeks. Started Nov 2016; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02954692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954692.